News
AKESF
12.00
0.00%
0.00
Guotai Haitong Keeps Their Buy Rating on Akeso, Inc. (9926)
TipRanks · 3d ago
Akeso Sets 2026 AGM to Approve Accounts, Board Slate and Capital-Issuance Mandate
TipRanks · 4d ago
BOCOM International Holdings Company Keeps Their Buy Rating on Akeso, Inc. (9926)
TipRanks · 5d ago
Jefferies Keeps Their Buy Rating on Akeso, Inc. (9926)
TipRanks · 5d ago
Huatai Securities Remains a Buy on Akeso, Inc. (9926)
TipRanks · 6d ago
Bank of America Securities Reaffirms Their Buy Rating on Akeso, Inc. (9926)
TipRanks · 6d ago
CLSA Sticks to Their Buy Rating for Akeso, Inc. (9926)
TipRanks · 6d ago
CICC Reaffirms Their Buy Rating on Akeso, Inc. (9926)
TipRanks · 06/02 05:17
Akeso, Inc. (9926) Receives a Hold from Bernstein
TipRanks · 06/01 00:58
Akeso’s ivonescimab trial at ASCO plenary signals potential new lung cancer standard
TipRanks · 05/31 22:38
Akeso lung cancer drug improved survival, challenging standard treatment
Seeking Alpha · 05/31 16:21
Akeso, Inc. (9926) Gets a Hold from Bernstein
TipRanks · 05/28 11:19
Summit downgraded at H.C. Wainwright after Merck data for sac-TMT
Seeking Alpha · 05/22 15:46
Summit Therapeutics falls after update on Akeso-partnered lung cancer trial
Seeking Alpha · 05/01 13:59
Huafu Securities Reaffirms Their Buy Rating on Akeso, Inc. (9926)
TipRanks · 04/30 07:11
Nomura Sticks to Its Hold Rating for Akeso, Inc. (9926)
TipRanks · 04/24 00:29
First Shanghai Securities Sticks to Their Buy Rating for Akeso, Inc. (9926)
TipRanks · 04/15 06:38
Akeso, Inc. (9926) Gets a Buy from Shenwan Hongyuan
TipRanks · 04/15 06:37
KeyBanc Reaffirms Their Buy Rating on Akeso, Inc. (9926)
TipRanks · 04/09 06:27
Akeso, Inc. (9926) Receives a Buy from Guotai Haitong
TipRanks · 04/04 14:55
More
Webull provides a variety of real-time AKESF stock news. You can receive the latest news about Akeso through multiple platforms. This information may help you make smarter investment decisions.
About AKESF
Akeso Inc is an investment holding company dedicated to the research, development, manufacturing and commercialization of antibody drugs that are affordable to patients worldwide. The Company’s programs covering the therapeutic areas of oncology, autoimmune and metabolic diseases. The Company's products mainly include cadonilimab (PD-1/CTLA-4), ivonescimab (PD-1/VEGF), Ligufalimab (AK117, CD47), Pulocimab (AK109, VEGFR-2), ANNIKO (penpulimab, PD-1), and tagitanlimab (PD-L1) used in oncology fields as well as ebronucimab (PCSK9), ebdarokimab (IL-12/IL-23), and Gumokimab (AK111, IL-17) used in metabolic and autoimmune therapeutic fields.